CR9627A - Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof - Google Patents

Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof

Info

Publication number
CR9627A
CR9627A CR9627A CR9627A CR9627A CR 9627 A CR9627 A CR 9627A CR 9627 A CR9627 A CR 9627A CR 9627 A CR9627 A CR 9627A CR 9627 A CR9627 A CR 9627A
Authority
CR
Costa Rica
Prior art keywords
receptor modulators
progesterone receptor
cyanopyrrole
sulfonamide
formula
Prior art date
Application number
CR9627A
Other languages
English (en)
Inventor
Casey Mccomas
Andrew Fensome
Edward MELENSKI
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9627A publication Critical patent/CR9627A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Se describen los moduladores del receptor de la progesterona de formula (I), o una sal farmaceuticamente aceptable del mismo, Formula (I); en donde R1, R2, R3, R4, R5, R6 y R7 son como define en la presente, son utiles para la anticoncepcion y terapia de reemplazo hormonal; tambien se proporcionan productos que contienen estos compuestos.
CR9627A 2005-07-29 2007-12-20 Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof CR9627A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70400905P 2005-07-29 2005-07-29

Publications (1)

Publication Number Publication Date
CR9627A true CR9627A (es) 2008-03-06

Family

ID=37309001

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9627A CR9627A (es) 2005-07-29 2007-12-20 Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof

Country Status (22)

Country Link
US (1) US7291643B2 (es)
EP (1) EP1910285A1 (es)
JP (1) JP5185114B2 (es)
KR (1) KR20080031915A (es)
CN (1) CN101233104A (es)
AR (1) AR056005A1 (es)
AU (1) AU2006275833B2 (es)
BR (1) BRPI0614412A2 (es)
CA (1) CA2612977A1 (es)
CR (1) CR9627A (es)
EC (1) ECSP088147A (es)
GT (1) GT200600336A (es)
HN (1) HN2008000135A (es)
IL (1) IL188314A (es)
MX (1) MX2008001338A (es)
NO (1) NO20076683L (es)
PE (1) PE20070404A1 (es)
RU (1) RU2007148077A (es)
SA (1) SA06270246B1 (es)
TW (1) TW200734302A (es)
UA (1) UA92500C2 (es)
WO (1) WO2007016212A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
PE20070341A1 (es) * 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
TW200848019A (en) * 2007-03-06 2008-12-16 Wyeth Corp Aryl sulfonamides useful for modulation of the progesterone receptor
TW200848021A (en) * 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
CA2710293A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
CN105101959B (zh) 2012-11-05 2018-04-17 南特知识产权控股有限责任公司 作为刺猬信号传导通路的抑制剂的含有环状磺酰胺的衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680413A (en) * 1986-01-17 1987-07-14 Nippon Soda Co., Ltd. Process for the production of 3-phenyl-4-cyanopyrroles
US5310938A (en) 1987-07-29 1994-05-10 American Cyanamid Company Substituted arylpyrrole compounds
EP0339342A1 (de) 1988-04-23 1989-11-02 Bayer Ag N-Substituierte N-Amino-pyrrole
GB8903592D0 (en) 1989-02-16 1989-04-05 Boots Co Plc Therapeutic agents
DE4036645A1 (de) 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
JP2699024B2 (ja) 1990-11-22 1998-01-19 富士写真フイルム株式会社 新規な色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
AU5891494A (en) 1993-01-29 1994-08-15 Nippon Soda Co., Ltd. Heterocyclic derivative
KR100275222B1 (ko) 1995-06-07 2001-02-01 이노세 히로시 피롤 유도체 및 의약 조성물
US6013421A (en) 1996-07-19 2000-01-11 Fuji Photo Film Co., Ltd. Silver halide photographic light-sensitive material and image-forming method
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
MXPA03008142A (es) 2001-03-09 2003-12-12 Pfizer Prod Inc Nuevos compuestos antiinflamatorios de bencimidazol.
ATE323701T1 (de) 2001-03-09 2006-05-15 Pfizer Prod Inc Triazolopyridine als entzündungshemmende mittel
DE60205974T2 (de) 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
JP2006514110A (ja) 2002-11-11 2006-04-27 バイエル・ヘルスケア・アクチェンゲゼルシャフト Ip受容体アンタゴニストとしてのフェニルまたはヘテロアリールアミノアルカン誘導体
WO2004073594A2 (fr) 2003-02-12 2004-09-02 L'oreal Utilisation d’un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
US7582755B2 (en) 2004-04-27 2009-09-01 Wyeth Cyanopyrrole-containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos

Also Published As

Publication number Publication date
AU2006275833B2 (en) 2012-04-26
SA06270246B1 (ar) 2010-11-22
NO20076683L (no) 2008-02-04
AU2006275833A1 (en) 2007-02-08
CA2612977A1 (en) 2007-02-08
GT200600336A (es) 2007-05-28
PE20070404A1 (es) 2007-05-10
JP5185114B2 (ja) 2013-04-17
EP1910285A1 (en) 2008-04-16
KR20080031915A (ko) 2008-04-11
AR056005A1 (es) 2007-09-12
UA92500C2 (ru) 2010-11-10
IL188314A (en) 2012-09-24
BRPI0614412A2 (pt) 2016-11-22
US7291643B2 (en) 2007-11-06
IL188314A0 (en) 2008-04-13
HN2008000135A (es) 2010-08-19
MX2008001338A (es) 2008-03-25
TW200734302A (en) 2007-09-16
JP2009502947A (ja) 2009-01-29
WO2007016212A1 (en) 2007-02-08
RU2007148077A (ru) 2009-09-10
ECSP088147A (es) 2008-02-20
CN101233104A (zh) 2008-07-30
US20070027126A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR9627A (es) Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
CL2008000669A1 (es) Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras.
CR8517A (es) Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
UY29875A1 (es) Compuestos quimicos
UY26129A1 (es) Moduladores del receptor glucocorticoide
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
AR065135A1 (es) Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
UY27436A1 (es) Compuestos químicos
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
AR064692A1 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
AR054586A1 (es) Uso de moduladores del receptor de progesterona
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
UY30736A1 (es) Compuestos quimicos 537
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
GT200600335A (es) Moduladores del receptor de progesterona cianopirrol-fenil amida y usos de los mismos
ECSP078043A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
HN2009001441A (es) Compuestos de 2- aminopirimidina como potentes inhibidores de hsp-90
UY29625A1 (es) Uso de moduladores no esteroides de receptores de progesterona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)